|
Vaccine pharmacovigilance in India: Current context and future perspective
Bikash Ranjan Meher
Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
Correspondence Address:
Dr. Bikash Ranjan Meher
Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha
India
Pharmacovigilance of vaccines is of paramount importance to promote the safe use of vaccines among their recipients. India launched the Adverse Events Following Immunization (AEFI) surveillance program in 1986 for monitoring suspected adverse events following immunization and since then, the AEFI surveillance guideline has been updated periodically, with the latest being in 2015. The successful AEFI surveillance program in India required the concerted effort of all stakeholders such as National AEFI Secretariat, National Technical Collaborating Centre, Central Drug Standard Control Organization, marketing authorization holder, and health-care professionals.
How to cite this article:
Meher BR. Vaccine pharmacovigilance in India: Current context and future perspective.Indian J Pharmacol 2019;51:243-247
|
How to cite this URL:
Meher BR. Vaccine pharmacovigilance in India: Current context and future perspective. Indian J Pharmacol [serial online] 2019 [cited 2023 Sep 21 ];51:243-247
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2019;volume=51;issue=4;spage=243;epage=247;aulast=Meher;type=0 |
|
